In one paragraphArticle in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Tayná Rodrigues OlegárioMedicinal Organic Synthesis Laboratory of Paraíba (LASOM-PB), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.
Marília Cecília da SilvaComputational Quantum Chemistry Laboratory, Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.
Rodrigo CristianoMedicinal Organic Synthesis Laboratory of Paraíba (LASOM-PB), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.ORCID https://orcid.org/0000-0002-5044-377X Euzébio Guimarães BarbosaComputational Pharmaceutical Chemistry Laboratory, Faculty of Pharmacy, Federal University of Rio Grande do Norte, Natal 59078-970, Rio Grande do Norte, Brazil.
Aline Dias da PurificaçãoCenter for the Research and Advancement of Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-3127-7585 Marina Sena MendesCenter for the Research and Advancement of Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7144-9989 Diogo BoerinCenter for the Research and Advancement of Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, São Paulo, Brazil.
Maria Cristina NonatoCenter for the Research and Advancement of Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-4916-1505 Claudio Gabriel Lima-JuniorMedicinal Organic Synthesis Laboratory of Paraíba (LASOM-PB), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Quinoline-4-carboxylic acid derivatives are privileged scaffolds in drug discovery, with potential as inhibitors of human dihydroorotate dehydrogenase (
Identifiers
PMID42146252
PMCPMC13176990
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390